News Desk
Daily coverage of the 2026 peptide regulatory wave — FDA action, PCAC proceedings, compounding pharmacy industry moves, telehealth pivots, and clinical research developments.
Regulatory · Market · Research · RSS
- market
Huberman Lab Drops 3-Hour Peptides Masterclass With Dr. Abud Bakri
Huberman Lab aired a three-hour peptide deep dive with Dr. Abud Bakri on BPC-157, GHK-Cu, epitalon, GLP-1s, and the evidence gap driving todays peptide boom.
Jun 1, 2026
- regulatory
Undark-STAT Investigation Reveals Hidden History of BPC-157
A Pulitzer Center-backed investigation traces Predrag Sikiric's 50-year quest behind BPC-157, questioning its evidence base ahead of July's FDA review.
May 31, 2026
- regulatory
Leana Wen Warns Wellness Peptide Craze Sidesteps Clinical Trials
Leana Wen warns wellness peptides replace clinical trials with self-experimentation, as med spas market unapproved compounds without safety details.
May 28, 2026
- market
CordenPharma Acquires AmbioPharm in Major Peptide CDMO Expansion
CordenPharma acquires AmbioPharm, adding two peptide API facilities (U.S. and China) with 400 employees, as peptide manufacturing becomes a strategic priority.
May 26, 2026
- regulatory
RFK Jr. Forces FDA Peptide Review as Young Men Inject at Epidemic Rate
RFK Jr. pushes FDA to reverse its 2023 peptide ban as a USA Today opinion piece documents young men injecting unregulated peptides at dangerous levels.
May 25, 2026
- regulatory
45% of Social-Media Peptide Buyers Visited the ER, New Survey Finds
A Sunlight survey of 1,000 U.S. peptide users finds social-media buyers are 3x more likely to land in the ER, while 75% used AI for dosing guidance.
May 24, 2026
- market
Fox News Examines 'Wild West' Peptide Craze as FDA Faces Pressure
Dr. Alex Tatem tells Fox News the peptide market boom poses risks and opportunities as the FDA weighs rule changes on several peptides this summer.
May 21, 2026
- market
Parabilis Medicines Files IPO After $2.3B Regeneron Peptide Alliance
Cambridge peptide biotech Parabilis debuts on Nasdaq after landing a $2.3 billion Regeneron partnership and posting 74% tumor response in Phase 1/2 trials.
May 20, 2026
- market
Vector Sciences Inks Peptide Manufacturing Deal for $80.8B Market
Vector Sciences and MPP Group partner to produce 22 shelf-stable peptides in a cGMP facility — the first major deal since the April FDA reclassification.
May 19, 2026
- market
Media Surge: Forbes, Men's Health Call for Peptide Oversight
Forbes warns peptides went mainstream without safeguards, as Men's Health reviews 100+ studies and Men's Fitness highlights BPC-157 research.
May 18, 2026
- regulatory
ECRI, ISMP Warn Wellness Peptide Market Outpaced Clinical Evidence
Joint white paper finds 35 of 36 BPC-157 studies were animal-only, gray-market purity as low as 5%, and heavy metal contamination in injectable products.
May 17, 2026
- market
Men in Their 40s Driving the Peptide Therapy Boom, New Reports Show
Men's Health and other outlets document surging interest from midlife men as the peptide boom broadens beyond biohackers, outrunning regulatory guardrails.
May 14, 2026
- research
AI Designs Better Peptide Antibiotics in Landmark UPenn Study
ApexGO, a new Penn AI system, designed antibiotic peptides that halted 85% of bacterial growth in lab tests and outperformed existing candidates.
May 13, 2026
- market
Peptide Revolution Reaches The Times, Oprah Daily, Globe and Mail
The Times examines the injectable peptide industry — joining Oprah Daily, the Globe and Mail, and Glossy in a global mainstream coverage wave.
May 12, 2026
- regulatory
Lancet Warns Peptide Craze Outpacing Regulation — BPC-157, Retatrutide
The Lancet warns social-media peptide use among youth is outpacing regulators, citing BPC-157, CJC-1295, and Retatrutide as primary concerns.
May 11, 2026
- regulatory
Australia’s TGA Warns on Illegal Peptides as Global Crackdown Widens
Australia’s TGA warns on illegal peptide use and border seizures as global regulators escalate enforcement ahead of July’s FDA PCAC meeting on seven compounds.
May 10, 2026
- regulatory
Week Ahead: Global Peptide Warnings, GLP-1 Comment Prep, PCAC Watch
Australia’s TGA peptide warning sets international tone, GLP-1 503B comment prep begins, and PCAC briefing materials for July remain anticipated.
May 10, 2026
- market
Media Wave Converges on Unapproved Peptide Injections — WSJ, SciAm, FT
WSJ, Scientific American, FT, and The Conversation all covered unapproved peptide injections in one week — a media turning point for the peptide debate.
May 7, 2026
- research
PubMed Digest — May 2026: BPC-157, MOTS-c, LL-37 Research Updates
Recent peer-reviewed publications on BPC-157, MOTS-c, GHK-Cu, Epitalon, and LL-37 — systematic reviews, mechanistic studies, and antimicrobial advances.
May 7, 2026
- regulatory
FDA Compounding Pharmacy Enforcement Intensifies Ahead of July PCAC
Compounding pharmacy enforcement is intensifying with FDA warning letters and a GLP-1 503B exclusion proposal ahead of the July PCAC peptide meeting.
May 6, 2026
- market
The Peptide Problem: Major Media Outlets Question Hype vs. Evidence
Major media outlets question whether demand for peptide therapies has outpaced the science behind them, ahead of a critical FDA review in July.
May 6, 2026
- regulatory
Melanotan II Tanning Trend Draws Scrutiny Ahead of July PCAC Review
WWD covers the Melanotan II tanning trend ahead of July PCAC review, highlighting the regulatory stakes for a peptide at the center of beauty and FDA policy.
May 5, 2026
- regulatory
FDA Semaglutide Decision Signals Tougher Peptide Compounding Standard
The FDA's April 30 proposal to end large-scale GLP-1 compounding uses the same clinical-need standard that will govern peptide compounding after PCAC.
May 4, 2026
- regulatory
FDA Proposes Excluding GLP-1 Drugs From 503B Compounding List
Test description.
May 3, 2026
- regulatory
FDA Sets July PCAC Meeting to Review Seven Peptide Therapies
The FDA has scheduled a July 2026 PCAC meeting to review seven peptide therapies including BPC-157, marking a potential shift in regulatory approach.
May 1, 2026
- market
Post-April 15, Where You Live Matters More Than You Think
Federal peptide reclassification sets the floor; state pharmacy boards set the ceiling. Ten states plus DC keep restrictive regimes that add real friction.
Apr 29, 2026
- market
The Telehealth Brands Most Likely to Pivot Into Peptides After PCAC
GLP-1 telehealth providers have the prescribers, compounding ties, and DTC marketing muscle to dominate peptides after PCAC. Who's positioning, and the impact.
Apr 28, 2026
- research
BPC-157: What the Research Actually Shows (And What It Doesn't)
BPC-157 has the strongest practitioner reputation of the reclassified peptides. An honest read on preclinical breadth, human trial gaps, and what it means.
Apr 27, 2026
- regulatory
Why the Research-Chemical Gray Market Is Not Going Away (And What to Do About It)
The April 15 reclassification cleared the prescription path for peptides. It did nothing to address the research-chemical channel — which is more dangerous now.
Apr 26, 2026
- regulatory
What the July 23–24 PCAC Meeting Will Actually Decide
The July PCAC meeting will determine final 503A Bulks List placement for the twelve reclassified peptides. The three possible outcomes and what each means.
Apr 25, 2026
- market
Compounding Pharmacies Quietly Positioning Ahead of July PCAC Meeting
The 90 days between the April 15 peptide reclassification and the July PCAC meeting are when the supply chain repositions. What's happening, and why it matters.
Apr 24, 2026
- regulatory
FDA Removes 12 Therapeutic Peptides From Category 2 — What the April 15 Action Means
The FDA's April 15 reclassification opens a legal compounding path for BPC-157, TB-500, and 10 other peptides. What it does — and doesn't — change.
Apr 23, 2026